Supplementary Figure 2: Clinical timelines for the four patients with uncharacterized HER2 mutations, as well as detailed clinicopathological features. | Nature Genetics

Supplementary Figure 2: Clinical timelines for the four patients with uncharacterized HER2 mutations, as well as detailed clinicopathological features.

From: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

Supplementary Figure 2: Clinical timelines for the four patients with uncharacterized HER2 mutations, as well as detailed clinicopathological features.

Patient histories are shown from breast cancer diagnosis until metastatic biopsy sequenced in this study; arrows represent distinct therapies and durations, described in the key (upper right). Asterisks demarcate the diagnosis of metastatic disease in each case.

Back to article page